news
Amgen wins patent block on Sanofi drug rival
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
List view / Grid view
Praluent (alirocumab)
news
NICE recommends five drugs to treat four different conditions
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
news
NICE recommends alirocumab and evolocumab in draft guidance
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
news
Positive results for Praluent in patients undergoing LDL apheresis therapy
23 March 2016 | By Victoria White
Patients who added Praluent to their existing treatment regimen significantly reduced the frequency of their apheresis therapy by 75% compared to placebo....
news
Heart UK questions absence of lipidologists after NICE limits cholesterol-busting drug use
12 February 2016 | By Victoria White
Heart UK has questioned why the NICE did not seek the expertise of lipidologists during its latest review of PCSK9 cholesterol-busting drugs...
news
NICE says ‘no’ to alirocumab in draft guidance
8 February 2016 | By Victoria White
NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...
news
EC approves LDL cholesterol treatment Praluent
28 September 2015 | By Victoria White
Praluent is the only EC-approved PCSK9 inhibitor that is available in two starting doses, offering two levels of efficacy...
news
FDA approves Praluent for the treatment of high LDL cholesterol
26 August 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Praluent (alirocumab) Injection - the first and only PCSK9 inhibitor approved in the US...
news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
news
Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol
19 November 2014 | By Sanofi / Regeneron Pharmaceuticals
Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…
news
Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
news
Sanofi and Regeneron present detailed positive results from four pivotal Alirocumab trials at ESC Congress 2014
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
news
New blockbuster drugs to more than triple acute coronary syndrome treatment market value by 2023
29 July 2014 | By GlobalData
The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome treatment market to more than triple in value...
news
Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction
16 October 2013 | By Sanofi
Alirocumab monotherapy reduced “bad” cholesterol three times more than ezetimibe...
